Proqr Therapeutics (PRQR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Sales | 1,491 | 1,314 | 703 | 815 | 963 |
| Gross Profit | 1,491 | 1,314 | 703 | 815 | 963 |
| Operating Expenses | 9,536 | 10,922 | 10,781 | 13,420 | 20,786 |
| Operating Income | -8,044 | -9,608 | -10,078 | -12,605 | -19,823 |
| Interest Expense | 0 | 0 | 0 | 3,862 | 0 |
| Other Income | 2,101 | 864 | 573 | 4,485 | -4,664 |
| Pre-tax Income | -5,944 | -8,744 | -9,505 | -11,983 | -24,487 |
| Income Tax | -45 | -46 | N/A | 3 | 70 |
| Net Income Continuous | -5,899 | -8,698 | -9,505 | -11,985 | -24,557 |
| Minority Interests | 316 | 17 | 84 | -4 | 14 |
| Net Income | $-6,215 | $-8,708 | $-9,589 | $-11,981 | $-24,571 |
| EPS Basic Total Ops | -0.08 | -0.11 | -0.12 | -0.17 | -0.34 |
| EPS Basic Continuous Ops | -0.07 | -0.11 | -0.12 | -0.16 | -0.34 |
| EPS Diluted Total Ops | -0.08 | -0.11 | -0.12 | -0.17 | -0.34 |
| EPS Diluted Continuous Ops | -0.07 | -0.11 | -0.12 | -0.16 | -0.34 |
| EBITDA(a) | $-7,348 | $-8,951 | $-9,489 | $-11,734 | $-19,273 |